Unitaid audited financial report for the year ended 31 December 2021
Unitaid Strategy 2023-2027
Financial Guidelines for Unitaid Grant Implementers (Frequently Asked Questions)
Unitaid 2017-2021 Strategy Review, Management Response, Dec 2021
Unitaid 2017-2021 Strategy Review, Final Report, Vol 2, Annexes
Unitaid 2017-202 Strategy Review, Final Report, Vol 1, Main report
Multipurpose prevention technologies: Technology landscape and potential for low- and middle-income countries
Financial guidelines for Unitaid grant implementers
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Global malaria diagnostic and artemisinin treatment commodities demand forecast: 2017 – 2021 Report (May 2018)
Fever Diagnostic Technology Landscape
Multi-disease diagnostics landscape for integrated management of HIV, HCV, TB and other coinfections
Hepatitis C medicines technology and market landscape
Unitaid’s approach to intellectual property
Discussion Paper: Ensuring that essential medicines are also affordable medicines: challenges and options
Discussion Paper: An economic perspective on delinking the cost of R&D from the price of medicines
Unitaid and the Government of Spain
About Unitaid (Saving lives faster)
Unitaid and the UK Government
Unitaid audited financial report for the year ended 31 December 2023
Partnership report: Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria
Unitaid audited financial report for the year ended 31 December 2022
HIV/AIDS diagnostics technology landscape – 3rd edition
Unitaid strategy 2013-2016
Key Performance Indicators 2013
Unitaid audited financial report for the year ended 31 December 2012
ACT Forecasting Report Q3-2012
Malaria diagnostics technology landscape – semi-annual update
Tuberculosis diagnostics technology & market landscape – semi-annual update
